ProfoundBio US Co.
🇺🇸United States
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1
Recruiting
- Conditions
- High Grade Epithelial Ovarian CancerHigh Grade Serous Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube CancerEndometrial CancerNon-small Cell Lung CancerEpidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)MesotheliomaBreast AdenocarcinomaTriple Negative Breast Cancer
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- ProfoundBio US Co.
- Target Recruit Count
- 529
- Registration Number
- NCT05579366
- Locations
- 🇺🇸
University of California Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸USOR HonorHealth, Phoenix, Arizona, United States
🇺🇸USOR Arizona Oncology Associates, Tucson, Arizona, United States
News
No news found